Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Tyler Crane

Nurse Practitioner Mocksville, NC Nurse Practitioner

NPI 1548711385 CMS profile 10629893

375 Hospital St Ste 200, Mocksville, NC 27028

Open in the dashboard

General payments

$1,373

84 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Tyler Crane of Mocksville, NC is reported in the CMS Open Payments database as having received $1,373 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $86 1
2023 General $139 8
2022 General $551 32
2021 General $596 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tyler Crane
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Tyler Crane were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Tyler Crane Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $596 $135 $40–$426 $132
2022 $551 $152 $48–$470 $149
2023 $139 $166 $54–$529 $160
2024 $86 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Pfizer Inc. $267 20 payments
  2. Novo Nordisk Inc $131 8 payments
  3. GlaxoSmithKline, LLC. $100 6 payments
  4. ANI Pharmaceuticals, Inc. $86 1 payment
  5. Novartis Pharmaceuticals Corporation $83 5 payments
  6. Abbott Laboratories $72 3 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $71 5 payments
  8. Lilly USA, LLC $67 5 payments
  9. Sanofi-Aventis U.S. LLC $65 4 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $57 4 payments
  11. Other $375 23 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $1,373 84 payments
Products named General payments · program years 2021–2024
  1. COLOGUARD DNA CAPTURE REAGENTS $184 14 payments
  2. ELIQUIS $150 10 payments
  3. TRELEGY ELLIPTA $100 6 payments
  4. PREMARIN $96 8 payments
  5. PURIFIED CORTROPHIN GEL $86 1 payment
  6. Ozempic $71 5 payments
  7. REYVOW $67 5 payments
  8. PAXLOVID $62 4 payments
  9. LEQVIO $60 3 payments
  10. Kerendia $57 4 payments
  11. Other $1,061 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

4,956

Median for Nurse Practitioner: 389

Drug cost

$364,333

Median for Nurse Practitioner: $21,885

Branded share of claims

20.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 96 $96,776
Mounjaro Tirzepatide Brand 35 $38,964
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 40 $35,383
Ozempic Semaglutide Brand 26 $25,673
Xarelto Rivaroxaban Brand 23 $22,142
Jardiance Empagliflozin Brand 22 $21,362
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $20,613
Trulicity Dulaglutide Brand 18 $17,917
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $15,635
Linzess Linaclotide Brand 18 $9,377

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$53,480

Of which drugs: $4,015

Medicare patients

178

Average age 74

Services billed

2,090

106 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Chronic kidney disease 38%
Diabetes 30%
Depression 26%
Ischemic heart disease 24%
COPD 20%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 12 12 $944
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 18 18 $394
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 213 $152

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record